Enhancement of antimicrobial activity of pump inhibitors associating drugs
with the continuous emergence of pathogenic resistance to conventional drugs through efflux pumps, increasing efforts are directed toward discovering efflux inhibitory molecules. in this study three P-glycoprotein (P13CP, P22CP, P34CP) efflux-inhibitors (EIs), belonging to the series of phenoxymethy...
Gespeichert in:
| Veröffentlicht in: | Journal of infection in developing countries 2019-02, Vol.13 (2), p.162-164 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 164 |
|---|---|
| container_issue | 2 |
| container_start_page | 162 |
| container_title | Journal of infection in developing countries |
| container_volume | 13 |
| creator | Usai, Donatella Donadu, Matthew Bua, Alessandra Molicotti, Paola Zanetti, Stefania Piras, Sandra Corona, Paola Ibba, Roberta Carta, Antonio |
| description | with the continuous emergence of pathogenic resistance to conventional drugs through efflux pumps, increasing efforts are directed toward discovering efflux inhibitory molecules.
in this study three P-glycoprotein (P13CP, P22CP, P34CP) efflux-inhibitors (EIs), belonging to the series of phenoxymethylquinoxalines capable to restore/potentiate the antiproliferative activity of doxorubicin and vincristine against human tumor cell lines and different antibiotics against clinical isolates, were investigated on 10 clinical strains of Candida and 12 clinical and ATCC strains of Gram positive and Gram-negative bacteria.
MFC values of FLC were reduced in all Candida strains by the P22CP and P34CP inhibitors, and in 5/10 fungal strains by the P13CP inhibitor.
novel antibiotics with new modes of action are urgently required to suppress the rise of MDR bacteria. An alternative approach would be to identify molecules that can interfere with the process of efflux. |
| doi_str_mv | 10.3855/jidc.11102 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2353014880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2353014880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-b90a62a94d5951db3df3e4b838512881fcc0972032bd656df704e285b220abd83</originalsourceid><addsrcrecordid>eNpdkF1LwzAUhoMobk5v_AFS8EaEzpOk6dJLGfOLgTd6XfLVLaNNa5IK-_d2bop4dQ6ch5f3PAhdYphSztjdxmo1xRgDOUJjXMxISnIOx3_2EToLYQPACsrwKRpRAjSnjIzRy8KthVOmMS4mbZUIF21jlW-lFXUiVLSfNm53l65vusS6tZU2tj4kIoRWWRGtWyXa96twjk4qUQdzcZgT9P6weJs_pcvXx-f5_TJVlOOYygJETkSRaVYwrCXVFTWZ5MMrmHCOK6Vg6A2USJ2zXFczyAzhTBICQmpOJ-hmn9v59qM3IZaNDcrUtXCm7UNJKKOAM85hQK__oZu2925oVxKWAwbIZnSgbvfU8HYI3lRl520j_LbEUO4MlzvD5bfhAb46RPayMfoX_VFKvwBduXXl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2560100473</pqid></control><display><type>article</type><title>Enhancement of antimicrobial activity of pump inhibitors associating drugs</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Usai, Donatella ; Donadu, Matthew ; Bua, Alessandra ; Molicotti, Paola ; Zanetti, Stefania ; Piras, Sandra ; Corona, Paola ; Ibba, Roberta ; Carta, Antonio</creator><creatorcontrib>Usai, Donatella ; Donadu, Matthew ; Bua, Alessandra ; Molicotti, Paola ; Zanetti, Stefania ; Piras, Sandra ; Corona, Paola ; Ibba, Roberta ; Carta, Antonio</creatorcontrib><description>with the continuous emergence of pathogenic resistance to conventional drugs through efflux pumps, increasing efforts are directed toward discovering efflux inhibitory molecules.
in this study three P-glycoprotein (P13CP, P22CP, P34CP) efflux-inhibitors (EIs), belonging to the series of phenoxymethylquinoxalines capable to restore/potentiate the antiproliferative activity of doxorubicin and vincristine against human tumor cell lines and different antibiotics against clinical isolates, were investigated on 10 clinical strains of Candida and 12 clinical and ATCC strains of Gram positive and Gram-negative bacteria.
MFC values of FLC were reduced in all Candida strains by the P22CP and P34CP inhibitors, and in 5/10 fungal strains by the P13CP inhibitor.
novel antibiotics with new modes of action are urgently required to suppress the rise of MDR bacteria. An alternative approach would be to identify molecules that can interfere with the process of efflux.</description><identifier>ISSN: 1972-2680</identifier><identifier>ISSN: 2036-6590</identifier><identifier>EISSN: 1972-2680</identifier><identifier>DOI: 10.3855/jidc.11102</identifier><identifier>PMID: 32036352</identifier><language>eng</language><publisher>Italy: Journal of Infection in Developing Countries</publisher><subject>Antibiotics ; Antimicrobial agents</subject><ispartof>Journal of infection in developing countries, 2019-02, Vol.13 (2), p.162-164</ispartof><rights>Copyright (c) 2019 Donatella Usai, Matthew Donadu, Alessandra Bua, Paola Molicotti, Stefania Zanetti, Sandra Piras, Paola Corona, Roberta Ibba, Antonio Carta.</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-b90a62a94d5951db3df3e4b838512881fcc0972032bd656df704e285b220abd83</citedby><orcidid>0000-0001-7681-6194</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32036352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Usai, Donatella</creatorcontrib><creatorcontrib>Donadu, Matthew</creatorcontrib><creatorcontrib>Bua, Alessandra</creatorcontrib><creatorcontrib>Molicotti, Paola</creatorcontrib><creatorcontrib>Zanetti, Stefania</creatorcontrib><creatorcontrib>Piras, Sandra</creatorcontrib><creatorcontrib>Corona, Paola</creatorcontrib><creatorcontrib>Ibba, Roberta</creatorcontrib><creatorcontrib>Carta, Antonio</creatorcontrib><title>Enhancement of antimicrobial activity of pump inhibitors associating drugs</title><title>Journal of infection in developing countries</title><addtitle>J Infect Dev Ctries</addtitle><description>with the continuous emergence of pathogenic resistance to conventional drugs through efflux pumps, increasing efforts are directed toward discovering efflux inhibitory molecules.
in this study three P-glycoprotein (P13CP, P22CP, P34CP) efflux-inhibitors (EIs), belonging to the series of phenoxymethylquinoxalines capable to restore/potentiate the antiproliferative activity of doxorubicin and vincristine against human tumor cell lines and different antibiotics against clinical isolates, were investigated on 10 clinical strains of Candida and 12 clinical and ATCC strains of Gram positive and Gram-negative bacteria.
MFC values of FLC were reduced in all Candida strains by the P22CP and P34CP inhibitors, and in 5/10 fungal strains by the P13CP inhibitor.
novel antibiotics with new modes of action are urgently required to suppress the rise of MDR bacteria. An alternative approach would be to identify molecules that can interfere with the process of efflux.</description><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><issn>1972-2680</issn><issn>2036-6590</issn><issn>1972-2680</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkF1LwzAUhoMobk5v_AFS8EaEzpOk6dJLGfOLgTd6XfLVLaNNa5IK-_d2bop4dQ6ch5f3PAhdYphSztjdxmo1xRgDOUJjXMxISnIOx3_2EToLYQPACsrwKRpRAjSnjIzRy8KthVOmMS4mbZUIF21jlW-lFXUiVLSfNm53l65vusS6tZU2tj4kIoRWWRGtWyXa96twjk4qUQdzcZgT9P6weJs_pcvXx-f5_TJVlOOYygJETkSRaVYwrCXVFTWZ5MMrmHCOK6Vg6A2USJ2zXFczyAzhTBICQmpOJ-hmn9v59qM3IZaNDcrUtXCm7UNJKKOAM85hQK__oZu2925oVxKWAwbIZnSgbvfU8HYI3lRl520j_LbEUO4MlzvD5bfhAb46RPayMfoX_VFKvwBduXXl</recordid><startdate>20190228</startdate><enddate>20190228</enddate><creator>Usai, Donatella</creator><creator>Donadu, Matthew</creator><creator>Bua, Alessandra</creator><creator>Molicotti, Paola</creator><creator>Zanetti, Stefania</creator><creator>Piras, Sandra</creator><creator>Corona, Paola</creator><creator>Ibba, Roberta</creator><creator>Carta, Antonio</creator><general>Journal of Infection in Developing Countries</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8C1</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7681-6194</orcidid></search><sort><creationdate>20190228</creationdate><title>Enhancement of antimicrobial activity of pump inhibitors associating drugs</title><author>Usai, Donatella ; Donadu, Matthew ; Bua, Alessandra ; Molicotti, Paola ; Zanetti, Stefania ; Piras, Sandra ; Corona, Paola ; Ibba, Roberta ; Carta, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-b90a62a94d5951db3df3e4b838512881fcc0972032bd656df704e285b220abd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Usai, Donatella</creatorcontrib><creatorcontrib>Donadu, Matthew</creatorcontrib><creatorcontrib>Bua, Alessandra</creatorcontrib><creatorcontrib>Molicotti, Paola</creatorcontrib><creatorcontrib>Zanetti, Stefania</creatorcontrib><creatorcontrib>Piras, Sandra</creatorcontrib><creatorcontrib>Corona, Paola</creatorcontrib><creatorcontrib>Ibba, Roberta</creatorcontrib><creatorcontrib>Carta, Antonio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Public Health Database</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of infection in developing countries</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Usai, Donatella</au><au>Donadu, Matthew</au><au>Bua, Alessandra</au><au>Molicotti, Paola</au><au>Zanetti, Stefania</au><au>Piras, Sandra</au><au>Corona, Paola</au><au>Ibba, Roberta</au><au>Carta, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancement of antimicrobial activity of pump inhibitors associating drugs</atitle><jtitle>Journal of infection in developing countries</jtitle><addtitle>J Infect Dev Ctries</addtitle><date>2019-02-28</date><risdate>2019</risdate><volume>13</volume><issue>2</issue><spage>162</spage><epage>164</epage><pages>162-164</pages><issn>1972-2680</issn><issn>2036-6590</issn><eissn>1972-2680</eissn><abstract>with the continuous emergence of pathogenic resistance to conventional drugs through efflux pumps, increasing efforts are directed toward discovering efflux inhibitory molecules.
in this study three P-glycoprotein (P13CP, P22CP, P34CP) efflux-inhibitors (EIs), belonging to the series of phenoxymethylquinoxalines capable to restore/potentiate the antiproliferative activity of doxorubicin and vincristine against human tumor cell lines and different antibiotics against clinical isolates, were investigated on 10 clinical strains of Candida and 12 clinical and ATCC strains of Gram positive and Gram-negative bacteria.
MFC values of FLC were reduced in all Candida strains by the P22CP and P34CP inhibitors, and in 5/10 fungal strains by the P13CP inhibitor.
novel antibiotics with new modes of action are urgently required to suppress the rise of MDR bacteria. An alternative approach would be to identify molecules that can interfere with the process of efflux.</abstract><cop>Italy</cop><pub>Journal of Infection in Developing Countries</pub><pmid>32036352</pmid><doi>10.3855/jidc.11102</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7681-6194</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1972-2680 |
| ispartof | Journal of infection in developing countries, 2019-02, Vol.13 (2), p.162-164 |
| issn | 1972-2680 2036-6590 1972-2680 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2353014880 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Antibiotics Antimicrobial agents |
| title | Enhancement of antimicrobial activity of pump inhibitors associating drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A14%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancement%20of%20antimicrobial%20activity%20of%20pump%20inhibitors%20associating%20drugs&rft.jtitle=Journal%20of%20infection%20in%20developing%20countries&rft.au=Usai,%20Donatella&rft.date=2019-02-28&rft.volume=13&rft.issue=2&rft.spage=162&rft.epage=164&rft.pages=162-164&rft.issn=1972-2680&rft.eissn=1972-2680&rft_id=info:doi/10.3855/jidc.11102&rft_dat=%3Cproquest_cross%3E2353014880%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2560100473&rft_id=info:pmid/32036352&rfr_iscdi=true |